SMPD2 and lung adenocarcinoma: For example, GW4869 inhibits the membrane-neutral sphingomyelinase (nSMase) and exosome/EV biogenesis; it has been tested in PC9 lung adenocarcinoma cells, counteracting the antagonistic effects of gefitinib and cisplatin, which are widely used for NSCLC patient treatment [161].